secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2026-03-13T23:59:59+00:00
Accession:  0001999371-26-005742
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix reports Q4 2025 net loss $46.9M; TONMYA launch shows ~4,200 prescriptions
-------------------------------------------------------------------------------

- Net loss available to common stockholders for Q4 2025 was $46.9M ($3.98/share) vs $22.1M ($9.77/share) in Q4 2024.
- Full year 2025 net product revenue $13.1M, including TONMYA launch from Nov 17–Dec 31: $1.4M.
- TONMYA launch-to-date (Nov 17,2025–Feb 27,2026): >1,500 HCPs prescribed, ~2,500 patients initiated, ~4,200 cumulative prescriptions.
- Cash and equivalents $207.6M as of Dec 31, 2025 (up from $98.8M); subsequent ATM raised $8.6M.
- Cash runway expected into Q1 2027; shares outstanding 13.4M as of March 11, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937126005742/0001999371-26-005742-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937126005742/tonix-8k_031326.htm
  HTML page:      https://secwatch.observer/filing/0001999371-26-005742

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer